Author Archive: Jeremy Parkinson

Stocks Tumble On News Senate Tax Plan To Delay Corporate Tax Cut Until 2019

Stocks Tumble On News Senate Tax Plan To Delay Corporate Tax Cut Until 2019

Confirming reports from earlier this week that the Senate GOP tax plan would delay the corporate tax cut for (at least) one year, a move that would strip the proposed tax reform of its most potent benefit, moments ago the Wapo reported that in a few hours, Senate Republicans will propose delaying a cut in the corporate tax […]
Gold Prices Clear Monthly Opening Range & Initiate Bullish Series

Gold Prices Clear Monthly Opening Range & Initiate Bullish Series

Gold prices appear to be breaking out of a near-term range, with the precious metal at risk of exhibiting a more bullish behavior as it starts to carve a series of higher highs & lows. Bullion may stay bid ahead of the Federal Open Market Committee’s (FOMC) last 2017-meeting on December 13 as the precious metal […]
Trump Blames Japan But Exonerates China Over Trade

Trump Blames Japan But Exonerates China Over Trade

Post Brexit Britain needs to take notice of the comments and sub-text of Donald Trump and his administration about trade between friends and rivals. Mr Trump is engaged on a 12-day Asian tour and has visited close ally Japan and China a nation with which relations could be regarded as less cordial. Whilst visiting Japan, […]
EC
                        
                        Tupperware Brands (TUP): 20 Years Of Uninterrupted Dividends And A 4.6% Yield, But How Safe Is The Payout?

EC Tupperware Brands (TUP): 20 Years Of Uninterrupted Dividends And A 4.6% Yield, But How Safe Is The Payout?

While interest rates are slowly rising, they remain at historically low levels. As a result, many income-focused investors continue to search for the best high dividend stocks to meet their long-term investing needs. High dividend stocks can be an appealing way to fund a portion of retirement through dividends rather than the selling of shares, but high-yields can sometimes be […]
Johnson Controls’ (JCI) Q4 Earnings In Line, Up Y/Y

Johnson Controls’ (JCI) Q4 Earnings In Line, Up Y/Y

Johnson Controls International plc (JCI – Free Report) is a supplier of automotive interiors, batteries, and other control equipment. The company is focused on a comprehensive cost saving program along with improving productivity. Estimate Trend & Surprise History Investors should note that Zacks Consensus Estimate for earnings for fourth-quarter fiscal 2017 has remained unchanged over the past month. […]
Claims Have Shaken Off Hurricane Impact

Claims Have Shaken Off Hurricane Impact

Initial jobless claims came in slightly higher than expected at 239,000 for the week ending November 4th, versus 232,000 expected and 229,000 last week. Continuing claims were slightly weaker, rising to 1.901mm versus 1.885 expected and 1.884 previously. While the uptick wasn’t positive, the trend is still very much “down and to the right”. The […]
Markets: Technology Leads The Way

Markets: Technology Leads The Way

My Swing Trading Approach With the weakness we are seeing early on, there is little reason for me to buy anything early on. It is possible that I will also entertain some short setups, depending on how persistent the sell-off is throughout the day.  Indicators VIX – Spiked early on, only to get pushed lower by […]
Stocks Sink As Tax-Cut Hopes Fade, Junk Bonds Hit 8-Month Lows

Stocks Sink As Tax-Cut Hopes Fade, Junk Bonds Hit 8-Month Lows

Sell the news? Stocks are slumping (following Japan’s overnight volatility) as traders await tax-cut legislation from the House Ways and Means Committee (and The Senate will also release its own version). High-Tax companies are underperforming… And Junk bonds just hit the lowest since March… Whether this selling due to disappointment in what is expected to […]
ADMA Biologics Announces Pricing Of Follow-On Offering

ADMA Biologics Announces Pricing Of Follow-On Offering

RAMSEY, N.J., Nov. 09, 2017 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that develops, manufactures and markets specialty plasma-based biologics designed to treat Primary Immune Deficiency Disease (“PIDD”) and the prevention and treatment of certain infectious immunological diseases, today announced the pricing […]